Prognostic Factors in Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma Treated with Selective Intra-arterial Chemotherapy

References

1. ↵
   Salcman M. Glioblastoma and malignant astrocytoma. In: Kaye A, Laws E, Jr. eds. Brain Tumors: An Encyclopedic Approach. Edinburgh: Churchill Livingstone; 1995; 449–477
2. ↵
   Shugg D, Allen B, Blizzard L, Dwyer T. Brain cancer incidence, mortality and case survival: observations from two Australian cancer registries. Int J Cancer 1994;59:765-770

   CrossRefPubMedWeb of Science
3. Greig N, Ries L, Yancik R, Rapoport S. Increasing annual incidence of primary malignant brain tumours in the elderly. J Natl Cancer Inst 1990;82:1621-1624

   CrossRefPubMedWeb of Science
4. Ahlbom A, Rodvall Y. Brain tumour trends. Lancet 1989;2:1272

   PubMed
5. ↵
   Wurschmidt F, Bunemann H, Heilmann HP. Prognostic factors in high-grade malignant glioma: a multivariate analysis of 76 cases with postoperative radiotherapy. Strahlenther Onkol 1995;171:315-321

   PubMed
6. ↵
   Salcman M. Survival in glioblastoma: historical perspective. Neurosurgery 1980;7:435-439

   CrossRefPubMed
7. ↵
   Fine H, Dear K, Loeffler J, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597

   CrossRefPubMedWeb of Science
8. ↵
   Sipos E, Brem H. New delivery systems for brain tumor therapy. Neurologic Clinics 1995;13:813-825

   PubMed
9. ↵
   Stewart DJ, Belanger JM, Grahovac A, et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery 1992;30:512-517

   PubMedWeb of Science
10. Dropcho EJ, Rosenfeld SS, Morawetz RB, et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. J Clin Oncol 1992;10:452-458

    Abstract/FREE Full Text
11. ↵
    Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 1983;52:997-1007

    CrossRefPubMedWeb of Science
12. ↵
    Mahaley MJ, Hipp S, EJ D, et al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 1989;70:371-378

    CrossRefPubMedWeb of Science
13. Neuwelt E, Howieson J, Frenkel E, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986;19:573-582

    CrossRefPubMedWeb of Science
14. ↵
    Rajan B, Ross G, Lim CC, et al. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer1994:1809-1815
15. ↵
    Salminen E, Nuutinen JM, Huhtala S. Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer1996:1918-1923
16. ↵
    Stenning S, Freedman LS, Bleehan NM. Prognostic factors for high grade glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party. J Neuro-Oncol 1990;9:47-55

    CrossRefPubMed
17. Watne K, Hannisdal E, Nome O, et al. Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery 1992;30:223-227

    PubMed
18. ↵
    Inamura R, Nomura R, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994;81:752-758

    CrossRefPubMedWeb of Science
19. ↵
    Cloughesy TF, Gobin YP, Black KL, et al. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neuro-Oncol 1997;35:121-131

    CrossRefPubMed
20. ↵
    Pasqualin A, Barone G, Cioffi F, Rosta L, Scienza R, Da Pian R. The relevance of anatomic and hemodynamic factors to a classification of cerebral arteriovenous malformations. Neurosurgery 1991;28:370-379

    CrossRefPubMedWeb of Science
21. ↵
    Kirby S, Brothers M, Irish W, et al. Evaluating glioma therapies: modeling treatments and predicting outcomes. J Natl Cancer Inst 1995;87:1884-1888

    CrossRefPubMedWeb of Science
22. ↵
    Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 1997;15:3129-3140

    Abstract
23. ↵
    Gehan E, Walker M. Prognostic factors for patients with brain tumors. Nat Cancer Inst Monogr 1977;46:189-195
24. ↵
    Green S, Byar D, Walker M, et al. Comparison of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121-132

    PubMedWeb of Science
25. ↵
    Hammoud M, Sawaya R, Shi W, Thall P, Leeds N. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neuro-Oncol 1996;27:65-73

    CrossRefPubMed
26. Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983;52:550-554

    CrossRefPubMedWeb of Science
27. ↵
    Kowalczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997;41:1028-1038

    CrossRefPubMedWeb of Science
28. ↵
    Durmaz R, Erken S, Arslantas A, Atasoy MA, Bal C, Tel E. Management of glioblastoma multiforme: with special reference to recurrence. Clin Neurol Neurosurg 1997;99:117-123

    CrossRefPubMed
29. ↵
    MacDonald DR, Cascino TL, Schold SCJ, Cairncross G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280

    Abstract
30. ↵
    Harsh G. Management of recurrent gliomas and meningiomas. In: Kaye A, Laws E, eds. Brain Tumors: An Encyclopedic Approach. Edinburgh: Churchill Livingstone; 1995:413–428
31. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-388

    CrossRefPubMedWeb of Science
32. ↵
    Burger P, Heinz E, Shibata T, et al. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurgery 1988;68:698-704

    CrossRefPubMedWeb of Science
33. ↵
    Reeves GI, Marks JE. Prognostic significance of lesion size for glioblastoma multiforme. Radiology 1979;132:469-471

    CrossRefPubMed
34. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338-343

    Abstract
35. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-388

    CrossRefPubMedWeb of Science
36. ↵
    Brem S. The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg 1976;23:440-453

    PubMed
37. ↵
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;333:1182-1186
38. ↵
    Russel DC, Rubinstein LJ. Pathology of Tumors of the Nervous System.. 5th ed. London: Arnold; 1989
39. ↵
    Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-372

    CrossRefPubMedWeb of Science
40. ↵
    Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513-520

    CrossRefPubMedWeb of Science
41. ↵
    Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998;49:189-196

    CrossRefPubMedWeb of Science
42. ↵
    Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997;75:1269-1278

    CrossRefPubMedWeb of Science
43. ↵
    Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-618

    CrossRefPubMed
44. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. Cancer 1989;64:2014-2023

    CrossRefPubMedWeb of Science
45. ↵
    Kadota T, Nakagawa H, Kuroda C. Malignant glioma: evaluation with 3D time-of-flight MR angiography. Acta Radiol 1998;39:227-232

    PubMed
46. Less JR, Skallak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Research 1991;51:265-273

    Abstract/FREE Full Text
47. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Research 1994;54:4564-4568

    Abstract/FREE Full Text
48. ↵
    Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992;76:792-798

    PubMedWeb of Science